Last reviewed · How we verify

NCT04076514: pCND

The Role of Central Neck Dissection in Stage N0 Papillary Thyroid Carcinoma

Status unknown Last updated 14 July 2020
What this trial tests

trial testing central neck dissection in Papillary Thyroid Cancer in 20 participants. Status unknown.

Timeline
1 September 2020
Primary endpoint
30 September 2020
1 November 2020

Quick facts

Lead sponsorAssiut University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment20
Start date1 September 2020
Primary completion30 September 2020
Estimated completion1 November 2020
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Assiut University

Who can join

16 and older, any sex, with Papillary Thyroid Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The benefits of prophylactic central neck dissection (pCND) remain controversial in clinically node-negative (cN0) papillary thyroid carcinoma (PTC). This study main goal is to investigate benefits of prophylactic central neck dissection in clinically node-negative papillary thyroid carcinoma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Papillary Thyroid Cancer

Currently open trials in the same condition.

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04076514.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing